An update on gene therapy/transfer treatments for bladder dysfunction

Current Bladder Dysfunction Reports

Volumn 1, Issue 2, 2006, Pages 119-125

  Christ, George J ^a   Hodges, Steve J ^a   Melman, Arnold ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33845735373     PISSN: 19317212     EISSN: 19317220     Source Type: Journal    
DOI: 10.1007/s11884-006-0017-1     Document Type: Article

References (41)

1. Yoshimura N, Chancellor MB: Current and future pharmacological treatment for overactive bladder. J Urol 2002, 168: 1897-1913.
2. Andersson KE: The importance of the cholinergic system in neurourology. Eur Urol 1998, 34(Suppl 1): 6-9.
3. Andersson KE, Wein AJ: Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev 2004, 56: 581-631.
4. Melman A, Bar-Chama N, McCullough A, et al.: The first human trial for gene transfer therapy for the treatment of erectile dysfunction: preliminary results. Eur Urol 2005, 48: 314-318.
5. Abrams P, Cardozo L, Fall M, et al.: The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003, 61: 37-49.
6. DeLancey JO, Fowler CJ, Keane D, et al.: eds.: Pathophysiology in Incontinence, 1st International Consultation on Incontinence. Plymouth, UK: Plymbridge Distributors; 1999.
7. Hu TW, Wagner TH: Health-related consequences of overactive bladder: an economic perspective. BJU Int 2005, 96(Suppl 1): 43-45.
8. Stanton SL: Stress urinary incontinence. Ciba Found Symp 1990, 151: 182-194.
9. Wise B, Cardozo L: Urge incontinence and stress incontinence. Curr Opin Obstet Gynecol 1991, 3: 520-527.
10. Andersson KE: The overactive bladder: pharmacologic basis of drug treatment. Urology 1997, 50: 74-89.
11. Andersson KE: Advances in the pharmacological control of the bladder. Exp Physiol 1999, 84: 195-213.
12. Nehra A, Steers WD, Althof SE, et al.: Third international conference on the management of erectile dysfunction: linking pathophysiology and therapeutic response. J Urol 2003, 170: S3-5.
13. Christ GJ: K channels as molecular targets for the treatment of erectile dysfunction. J Androl 2002, 23: S10-19.
14. Christ GJ, Day N, Santizo C, et al.: Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo. Am J Physiol Heart Circ Physiol 2004, 287: H1544-1553.
15. Melman A: Gene transfer for the therapy of erectile dysfunction: progress in the 21st century. Int J Impot Res 2006, 18: 19-25.
16. Christ GJ: Gene therapy treatments for erectile and bladder dysfunction. Curr Urol Rep 2004, 5: 52-60.
17. Schultheiss D: Regenerative medicine in andrology: tissue engineering and gene therapy as potential treatment options for penile deformations and erectile dysfunction. Eur Urol 2004, 46: 162-169.
18. Karicheti V, Christ GJ: Physiological roles for K+ channels and gap junctions in urogenital smooth muscle: implications for improved understanding of urogenital function, disease and therapy. Curr Drug Targets 2001, 2: 1-20.
19. Archer SL: Potassium channels and erectile dysfunction. Vascul Pharmacol 2002, 38: 61-71.
20. Christ GJ, Rehman J, Day N, et al.: Intracorporal injection of hSlo cDNA in rats produces physiologically relevant alterations in penile function. Am J Physiol 1998, 275: H600-608.
21. Melman A, Zhao W, Davies KP, et al.: The successful long-term treatment of age related erectile dysfunction with hSlo cDNA in rats in vivo. J Urol 2003, 170: 285-290.
22. Melman A, Bar-Chama N, McCullough A, Davies K, Christ GJ: Results of the first human trial for gene transfer therapy for the treatment of erectile dysfunction [abstract 686]. In Program and Abstracts of the American Urological Association 2006 Annual Meeting. Atlanta, GA; May 20-25, 2006.
23. Huard J, Yokoyama T, Pruchnic R, et al.: Muscle-derived cell-mediated ex vivo gene therapy for urological dysfunction. Gene Ther 2002, 9: 1617-1626.
24. Lu SH, Cannon TW, Chermanski C, et al.: Muscle-derived stem cells seeded into acellular scaffolds develop calcium-dependent contractile activity that is modulated by nicotinic receptors. Urology 2003, 61: 1285-1291.
25. Otani M, Yoshida M, Iwashita H, et al.: Electroporation-mediated muscarinic M3 receptor gene transfer into rat urinary bladder. Int J Urol 2004, 11: 1001-1008.
26. Gries FA, Cameron NE, Low P, Ziegler D, eds: Textbook of Diabetic Neuropathy. Stuttgart: Theime Medical Publishers; 2003.
27. Goins WF, Yoshimura N, Phelan MW, et al.: Herpes simplex virus mediated nerve growth factor expression in bladder and afferent neurons: potential treatment for diabetic bladder dysfunction. J Urol 2001, 165: 1748-1754.
28. Apfel SC, Arezzo JC, Brownlee M, et al.: Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res 1994, 634: 7-12.
29. Sasaki K, Chancellor MB, Goins WF, et al.: Gene therapy using replication-defective herpes simplex virus vectors expressing nerve growth factor in a rat model of diabetic cystopathy. Diabetes 2004, 53: 2723-2730.
30. Chuang YC, Chou AK, Wu PC, et al.: Gene therapy for bladder pain with gene gun particle encoding pro-opiomelanocortin cDNA. J Urol 2003, 170: 2044-2048.
31. Chancellor MB, Yoshimura N: Treatment of interstitial cystitis. Urology 2004, 63: 85-92.
32. Chuang YC, Yang LC, Chiang PH, et al.: Gene gun particle encoding preproenkephalin cDNA produces analgesia against capsaicin-induced bladder pain in rats. Urology 2005, 65: 804-810.
33. Kanai AJ, Zeidel ML, Lavelle JP, et al.: Manganese superoxide dismutase gene therapy protects against irradiation-induced cystitis. Am J Physiol Renal Physiol 2002, 283: F1304-1312.
34. Greenberger JS, Epperly MW, Gretton J, et al.: Radioprotective gene therapy. Curr Gene Ther 2003, 3: 183-195.
35. Christ GJ, Day NS, Day M, et al.: Bladder injection of "naked" hSlo/pcDNA3 ameliorates detrusor hyperactivity in obstructed rats in vivo. Am J Physiol Regul Integr Comp Physiol 2001, 281: R1699-1709.
36. Brading AF: A myogenic basis for the overactive bladder. Urology 1997, 50: 57-73.
37. Heppner TJ, Herrera GM, Bonev AD, et al.: Ca2+ sparks and K(Ca) channels: novel mechanisms to relax urinary bladder smooth muscle. Adv Exp Med Biol 2003, 539: 347-357.
38. Herrera GM, Etherton B, Nausch B, Nelson MT: Negative feedback regulation of nerve-mediated contractions by KCa channels in mouse urinary bladder smooth muscle. Am J Physiol Regul Integr Comp Physiol 2005, 289: R402-R409.
39. Meredith AL, Thorneloe KS, Werner ME, et al.: Overactive bladder and incontinence in the absence of the BK large conductance Ca2+-activated K+ channel. J Biol Chem 2004, 279: 36746-36752.
40. Thorneloe KS, Meredith AL, Knorn AM, et al.: Urodynamic properties and neurotransmitter dependence of urinary bladder contractility in the BK channel deletion model of overactive bladder. Am J Physiol Renal Physiol 2005, 289: F604-610.
41. Petkov GV, Heppner TJ, Bonev AD, et al.: Low levels of K(ATP) channel activation decrease excitability and contractility of urinary bladder. Am J Physiol Regul Integr Comp Physiol 2001, 280: R1427-1433.